# JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations

Source: https://onco.cc/trials/nct06940401/  
OnCo record `nct06940401` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JS111 capsules (AP-L1898) in non-small-cell lung cancer, run by Suzhou Junjing BioSciences Co., Ltd., active and no longer recruiting.

## Summary

JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations is a phase 1/2 interventional study registered as NCT06940401 by Suzhou Junjing BioSciences Co., Ltd., with 44 participants enrolled, started 2025-04-30 and due to reach its primary completion in 2028-07-30. Interventions recorded: JS111 capsules (AP-L1898).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06940401
- Phase: 1/2
- Setting: A Phase I/II Clinical Study to Evaluate JS111 Capsules in Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations.
- Sponsor: Suzhou Junjing BioSciences Co., Ltd.
- Enrolled: 44

## Sources

- ClinicalTrials.gov NCT06940401: https://clinicaltrials.gov/study/NCT06940401

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06940401.json